To focus the analysis selectively on TIGIT or PD-1, we examined tumor growth in the prevention setting (i.e., the mAb was administered shortly after tumor implantation) where both anti-TIGIT and anti-PD-L1 exhibit single agent activity; in the therapeutic setting, anti-TIGIT is most effective when combined with anti-PD-L1. This evidence concerns the gene PDCD1 and neoplasm.